American Trust Has $636,000 Position in Insulet Co. (NASDAQ:PODD)

American Trust cut its stake in shares of Insulet Co. (NASDAQ:PODDGet Rating) by 5.6% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,388 shares of the medical instruments supplier’s stock after selling 142 shares during the quarter. American Trust’s holdings in Insulet were worth $636,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Blueshift Asset Management LLC lifted its holdings in Insulet by 80.2% during the 1st quarter. Blueshift Asset Management LLC now owns 2,964 shares of the medical instruments supplier’s stock worth $790,000 after buying an additional 1,319 shares during the period. AIA Group Ltd lifted its holdings in Insulet by 190.3% during the 1st quarter. AIA Group Ltd now owns 3,678 shares of the medical instruments supplier’s stock worth $980,000 after buying an additional 2,411 shares during the period. TD Asset Management Inc. lifted its stake in shares of Insulet by 18.6% in the 1st quarter. TD Asset Management Inc. now owns 44,991 shares of the medical instruments supplier’s stock valued at $11,985,000 after purchasing an additional 7,040 shares during the period. Swiss National Bank lifted its stake in shares of Insulet by 14.1% in the 1st quarter. Swiss National Bank now owns 298,677 shares of the medical instruments supplier’s stock valued at $79,565,000 after purchasing an additional 36,800 shares during the period. Finally, First Foundation Advisors lifted its stake in shares of Insulet by 27.9% in the 1st quarter. First Foundation Advisors now owns 1,187 shares of the medical instruments supplier’s stock valued at $316,000 after purchasing an additional 259 shares during the period.

Insider Transactions at Insulet

In other news, Director Shacey Petrovic sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $222.90, for a total value of $3,343,500.00. Following the transaction, the director now owns 13,695 shares in the company, valued at approximately $3,052,615.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other news, EVP Bret Christensen sold 2,900 shares of the business’s stock in a transaction that occurred on Wednesday, August 24th. The stock was sold at an average price of $264.24, for a total value of $766,296.00. Following the transaction, the executive vice president now owns 19,551 shares in the company, valued at approximately $5,166,156.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Shacey Petrovic sold 15,000 shares of the business’s stock in a transaction that occurred on Friday, July 1st. The stock was sold at an average price of $222.90, for a total value of $3,343,500.00. Following the completion of the transaction, the director now owns 13,695 shares in the company, valued at approximately $3,052,615.50. The disclosure for this sale can be found here. Company insiders own 0.90% of the company’s stock.

Insulet Stock Performance

Shares of PODD opened at $255.00 on Friday. The company has a debt-to-equity ratio of 3.28, a quick ratio of 3.54 and a current ratio of 4.69. The stock has a 50 day moving average price of $254.61 and a two-hundred day moving average price of $240.65. The firm has a market capitalization of $17.70 billion, a P/E ratio of 510.00 and a beta of 0.73. Insulet Co. has a 52 week low of $181.00 and a 52 week high of $324.81.

Insulet (NASDAQ:PODDGet Rating) last issued its quarterly earnings data on Thursday, August 4th. The medical instruments supplier reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of $0.22 by ($0.72). The company had revenue of $299.40 million for the quarter, compared to the consensus estimate of $290.87 million. Insulet had a return on equity of 13.83% and a net margin of 2.94%. The business’s revenue for the quarter was up 13.8% on a year-over-year basis. During the same period in the prior year, the firm posted $0.10 earnings per share. Equities analysts forecast that Insulet Co. will post 0.76 earnings per share for the current fiscal year.

Analyst Ratings Changes

A number of research analysts have recently issued reports on PODD shares. BTIG Research boosted their price objective on Insulet to $285.00 in a research note on Tuesday, August 9th. Canaccord Genuity Group boosted their price objective on Insulet from $250.00 to $290.00 and gave the company a “buy” rating in a research note on Monday, August 8th. Robert W. Baird boosted their price objective on Insulet from $245.00 to $300.00 and gave the company an “outperform” rating in a research note on Friday, August 5th. StockNews.com downgraded Insulet from a “hold” rating to a “sell” rating in a research note on Thursday. Finally, Morgan Stanley boosted their price objective on Insulet from $244.00 to $273.00 and gave the company an “equal weight” rating in a research note on Monday, August 8th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $295.23.

About Insulet

(Get Rating)

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. It offers Omnipod System, a self-adhesive disposable tubeless Omnipod device that is worn on the body for up to three days at a time, as well as its wireless companion, the handheld personal diabetes manager.

See Also

Institutional Ownership by Quarter for Insulet (NASDAQ:PODD)

Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.